REG - Arecor Therapeutics - Exercise of rollover options & Total Voting Rights

Arecor TherapeuticsAnnouncement

01/11/2023 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231101:nRSA0901Sa&default-theme=true

RNS Number : 0901S  Arecor Therapeutics PLC  01 November 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

Exercise of rollover options and Total Voting Rights

 

Cambridge, UK, 1 November 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that it has issued and allotted 1,332 new Ordinary Shares of
1 pence each in the share capital of the Company following an exercise of
options on 31 October 2023 at an exercise price of 1 pence per Ordinary Share.
The options exercised were part of the rollover of share options previously
granted under the Arecor Limited EMI Share Option Plan 2018 ("Option
Rollover"). Details of the Option Rollover are set out in the Company's
Admission Document.

 

Admission

Following the above transactions, application has been made for the 1,332 new
Ordinary Shares to be admitted to trading on AIM ("Admission") and dealings
are expected to commence on, or around, 7 November 2023. The new Ordinary
Shares will rank pari passu with the Company's existing Ordinary Shares.

 

The total number of Ordinary Shares in issue following Admission will be
30,626,986. Accordingly, the figure of 30,626,986 may be used by shareholders
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure and Transparency Rules.

 

-ENDS-

For more information, please contact:

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio. For further details
please see our website, www.arecor.com (http://www.arecor.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREASFFEANDFFA